Incremental Value of 11C Acetate Over 68Ga PSMA PET CT for Prostate Cancer Patients with Low-risk Clinical Factors - Sirong Chen

(Length of Presentation: 8 min)

The 68Ga-PSMA PET/CT has a high clinical impact for preoperative staging, restaging biochemical recurrence after radical prostatectomy, and treatment monitoring. Dr. Chen highlights the details of this trial with two objectives. They assessed 68 Ga-PSMA PET/CT in primary prostate cancer with different clinical risks and further studied the inclusion of 11 C-Acetate PET/CT to see if there was an incremental value over 68Ga-PSMA PET CT in any of the risk-stratified groups.

Biography:

Sirong Chen, MD, Department of Nuclear Medicine & PET, Hong Kong Sanatorium & Hospital, Village Road, Happy Valley, Hong Kong, Hong Kong
 
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe